Filters
Results 1 - 1 of 1
Results 1 - 1 of 1.
Search took: 0.018 seconds
AbstractAbstract
[en] The aim of our study was to comprehensively evaluate the most valuable metabolic parameters of cervical tumours and pelvic lymph nodes (PLN) by FDG-PET/CT to predict para-aortic lymph node (PALN) metastasis and stratify patients for surgical staging. The study included patients with locally advanced cervical cancer, negative PALN uptake on preoperative FDG-PET/CT, and para-aortic lymphadenectomy. Two senior nuclear medicine physicians expert in gynaecologic oncology reviewed all PET/CT exams, and extracted tumour SUVmax, MTV, and TLG, as well as PLN. Prognostic parameters of PALN involvement were identified using ROC curves and logistic regression analysis. One hundred and twenty-five consecutive locally advanced cervical cancer patients were included. The FDG-PET/CT false-negative rate was, respectively, 27.7% (13/47) and 5.1% (4/78) in patients with and without FDG-PET/CT PLN uptake. The AUC of cervical tumour size, SUVmax, MTV, and TLG was, respectively, 0.75 (0.62–0.87), 0.59 (0.44–0.76), 0.75 (0.60–0.90), and 0.71 (0.56–0.86). The AUC of PLN size, SUVmax, SUVmean, PLN SUVmax/Tumour SUVmax ratio, MTV, and TLG was, respectively, 0.57 (0.37–0.78), 0.82 (0.68–0.95), 0.77 (0.61–0.94), 0.85 (0.72–0.98), 0.69 (0.51–0.87), and 0.74 (0.57–0.91). The metabolic parameter showing the best trade-off between sensitivity and specificity to predict PALN involvement was the ratio between PLN and tumour SUVmax. The risk of PALN metastasis in FDG-PET/CT negative PLN patients is very low, so para-aortic lymphadenectomy does not seem justified. In patients with preoperative PLN uptake on FDG-PET/CT, surgical staging led to treatment modification in more than 25% of cases and should therefore be performed. Patients with more than one positive PLN and high PLN metabolic activity are at high risk of para-aortic extension and recurrence. Further prospective evaluation is required to consider intensified treatment modalities without prior PALN dissection.
Primary Subject
Source
Available from: http://dx.doi.org/10.1007/s00259-019-04659-z
Record Type
Journal Article
Journal
European Journal of Nuclear Medicine and Molecular Imaging; ISSN 1619-7070;
; CODEN EJNMA6; v. 47(5); p. 1252-1260

Country of publication
CARCINOMAS, EXTERNAL BEAM RADIATION THERAPY, FLUORINE 18, FLUORODEOXYGLUCOSE, FRACTIONATED IRRADIATION, GY RANGE 01-10, GY RANGE 10-100, HAZARDS, LYMPH NODES, METABOLISM, METASTASES, PELVIS, POSITRON COMPUTED TOMOGRAPHY, REGRESSION ANALYSIS, SENSITIVITY, SPECIFICITY, SURGERY, SURVIVAL CURVES, UPTAKE
ABSORBED DOSE RANGE, ANTIMETABOLITES, BETA DECAY RADIOISOTOPES, BETA-PLUS DECAY RADIOISOTOPES, BODY, COMPUTERIZED TOMOGRAPHY, DIAGNOSTIC TECHNIQUES, DISEASES, DRUGS, EMISSION COMPUTED TOMOGRAPHY, FLUORINE ISOTOPES, GY RANGE, HOURS LIVING RADIOISOTOPES, IRRADIATION, ISOMERIC TRANSITION ISOTOPES, ISOTOPES, LIGHT NUCLEI, LYMPHATIC SYSTEM, MATHEMATICS, MEDICINE, NANOSECONDS LIVING RADIOISOTOPES, NEOPLASMS, NUCLEAR MEDICINE, NUCLEI, ODD-ODD NUCLEI, RADIATION DOSE RANGES, RADIOISOTOPES, RADIOLOGY, RADIOTHERAPY, STATISTICS, THERAPY, TOMOGRAPHY
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue